Autolus Therapeutics plc (AUTL): Insider Trading, Congress Trades & Research | Tormere

AUTL

$1.28+1.59%visit website

Autolus Therapeutics plc

Market Cap

$341M

Live price × SEC shares (Aug 10, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

2.32

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

2.9

TTM to Jun 2026 · revenue

P/B

4.6

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	21,194	24,289	26,218	45,689	117,390
Cost of revenue	28,643	25,330	24,568	20,468	99,009
Research & development	27,892	35,633	21,210	27,898	112,633
Selling, general & administrative	36,280	35,795	39,953	41,161	153,189
Operating income	(71,621)	(72,466)	(59,513)	(43,838)	(247,438)
Interest expense	10,520	22,836	11,124	(2,674)	41,806
Pretax income	(78,586)	(91,515)	(70,735)	(38,646)	(279,482)
Income tax	532	(1,183)	863	465	677
Net income	(79,118)	(90,332)	(71,598)	(39,111)	(280,159)
EPS (basic) ($)	(0.30)		(0.27)	(0.15)	(1.06)
EPS (diluted) ($)	(0.30)		(0.27)	(0.15)	(1.06)
Weighted avg. shares (basic)	266,141		266,143	266,159
Weighted avg. shares (diluted)	266,141		266,143	266,159

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 11, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 14 more quarters, back to Mar 2022, with Tormere Pro.

Signals

Insider Velocity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

PPF Group a.s. · 2026-08-28

Analyst Consensus

Strong Buy

16 analysts

Velocity Score

23.98x

Avg Daily Selling (90d)

74.6 sh/day

Baseline Daily Selling

0.0 sh/day

Unique Sellers (90d)

1

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-09-02	2026-09-03	Piccina Cintia	U.S. CCO & Country Gen Manager	Sale	6,713	$2.34	$16K	13.3K	View

Recent News

Autolus Therapeutics plc (AUTL) Stock Price, News, Quote & History

Yahoo! Finance Canada · 2026-11-05

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026

Yahoo · 2026-11-04

Autolus Therapeutics To Present Clinical Update Abstracts At American Society of Hematology Meeting, December 12-15

Benzinga · 2026-11-04

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo · 2026-11-03

Autolus Therapeutics (NasdaqGS:AUTL) Stock Forecast & Analyst Predictions

Simply Wall St · 2026-11-02

HC Wainwright & Co. Assumes Autolus Therapeutics at Buy, Announces Price Target of $10

Benzinga · 2026-11-02

Autolus Therapeutics: Cheap On Sales, Still Far From Breakeven

SeekingAlpha · 2026-10-27

Autolus Therapeutics: Key Questions For The Near Term

SeekingAlpha · 2026-10-27

Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026

Yahoo · 2026-10-26

All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy

Yahoo Finance · 2026-10-05

Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026

Yahoo Finance · 2026-10-05

AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black

Yahoo Finance · 2026-09-12

Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis

Yahoo Finance · 2026-09-09

Autolus (AUTL) Q2 2026 Earnings Call Transcript

Yahoo Finance · 2026-08-18

Autolus Therapeutics Q2 Earnings Call Highlights

Yahoo Finance · 2026-08-11

Informational purposes only, not investment advice.